Health
Health
Medicine, public health and the drug pipeline, straight from the desks that cover them.
437 stories, newest first, oldest shown from October 6, 2026. Rebuilt just now.
'What does it say if a woman can't give birth in her own city?'The Southern Health Trust plans to temporarily transfer inpatient maternity services from Daisy Hill to Craigavon.
STAT+: Roche gets a lung cancer win with its KRAS drug divarasibOne of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which treats lung cancer.STAT+: Nonprofit Bon Secours Mercy Health strikes $5.7 billion deal for surgery center chainThe deal would make the Catholic system one of the largest operators of outpatient surgery centers.STAT+: HHS relaxes security, transparency rules for health record software used by hospitalsThe Trump administration removed several security, privacy and transparency requirements for vendors of EHR software.
Employers accuse UnitedHealth of overpaying medical claimsSix large US companies sued UnitedHealth Group, accusing the health insurance giant of overpaying for workers’ medical claims and driving up their costs. Aramark, Whirlpool, Grainger, Kraft Heinz Foods, Ralph Lauren and Sterling…
Survey: More Than Half of Women in States with Abortion Bans Wouldn’t Know Where to Get an Abortion if They Needed One, Up Since 2024More than half (53%) of reproductive-age women living in states with abortion-provision bans say they would not know where to go or where to find information if they needed an abortion, up from 43% in 2024, according to a new KFF…Women’s Experiences with Abortion, Access, and Concerns About Future PregnancyThis brief provides national estimates from the 2026 KFF Women’s Health Survey on reproductive age women’s experiences with abortion, the impact of Dobbs on abortion access and women’s concerns about future pregnancies, as well…Overview of President Trump’s Executive Actions Impacting LGBTQ+ HealthThis tracker examines Executive Actions taken by the Trump administration that have the potential to impact LGBTQ+ people’s health. It lists the action taken by date, provisions relevant to LGBTQ+ health, and describes potential…Microsoft's AI gives more accurate diagnoses than doctors, study findsMicrosoft says its AI system was around twice as accurate as doctors in diagnosing cases from a medical journal and from emergency room visits, as the tech giant looks to bring AI into clinical care. ...
Anthropic Files for IPO: S-1 Shows 9 of the 10 Largest Pharma Companies in the Fortune 500 Are Paying CustomersAnthropic filed for its IPO with the SEC on Monday, and its S-1 shows that 9 of the 10 largest pharmaceutical companies in the Fortune 500 each spent at least $100,000 with the company in the twelve months to September 30. Eight…WuXi AppTec raises revenue forecast again in the face of DoD court caseWuXi AppTec's dispute with the US Department of Defense over its designation as a Chinese military company isn't standing in the way of its performance: The manufacturer raised its 2026 guidance again and is accelerating ...Tracking Key Mental Health and Substance Use Policy Actions Under the Trump AdministrationA new KFF tracker highlights key federal policy actions during President Trump’s second term that concern issues related to mental health and substance use. The second Trump administration has emphasized law-and-order strategies…STAT+: House lawmaker probes PBMs for ‘punitive’ audits of independent pharmaciesA House lawmaker is investigating whether the three largest PMS targeted independent pharmacies withretaliatory audits.STAT+: GSK sees its return to cancer starting to pay offA decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.Roche’s changing plans show how MFN is complicating European drug launchesRoche will seek European approval for its promising new breast cancer pill giredestrant later than it once expected, highlighting how US drug pricing pressure may be affecting pharmaceutical companies’ launch strategies…Beyond cancer vaccine, how did Merck’s oncology pipeline do at #ESMO26?MADRID — Much of the coverage on Merck at the European Society for Medical Oncology congress centered on its Moderna-partnered cancer vaccine trial. But the company is actually at the meeting with more than two ...STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancerA Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancerAspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCsPlus news about Hutchmed, Johnson &; Johnson, Jazz Pharmaceuticals, Novartis, Roche and Oruka Therapeutics. Aspen, Bambusa both eye $135M IPOs: Aspen Neuroscience plans to sell 9.38 million shares {$ASPE} between $15 ...STAT+: Rising premiums, a sad Medicaid gathering, and a new fraud crackdownThe cost of health insurance is surging, and CMS presses ahead with a new fraud crackdown.#ESMO26: SystImmune/BMS and Hengrui detail data in EGFR-mutant lung cancerMADRID — Several drugmakers with antibody-drug conjugates are jockeying for a spot in EGFR-mutant non-small cell lung cancer patients who progress after AstraZeneca’s Tagrisso. And it seems that the most intriguing results are…Lilly’s music-loving, intense lead dealmaker knows what he wantsTwenty-two years ago, in a theater on the bucolic campus of Princeton University, a sophomore named Jacob Van Naarden portrayed the gambler Nathan Detroit in a production of the famous Broadway ...STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMOA targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancerSTAT+: Five biotech updates to read after ESMO this weekendModerna and Merck are racing to submit their personalized cancer vaccine for FDA approval, expected in 2027, according to Moderna CEO Stéphane Bancel.STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and moreBristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trialA virus that afflicts cows makes the jump to a humanFor the first time, a human has been infected with the Shamonda virus, according to French officials. The World Health Organization says broader transmission is unlikely.Corxel to take oral GLP-1 public in the US via SPACFor the second week in a row, a drug developer is going public via a special purpose acquisition company (SPAC), the blank-check vehicle that had faded out of favor but now appears ...BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer resultsBioNTech and DualityBio are mulling what to do next with trastuzumab pamirtecan in certain breast cancer patients after the antibody-drug conjugate delivered a “statistically significant, yet modest” success in a Phase 3 trial…'We're very busy' - Inside Wales' newest hospitalBBC Wales correspondent Owain Clarke visited the Grange Hospital following concerns about its safety.Can you tell ferritin levels from your face?Some creators are claiming they can spot "ferritin face". Doctors aren't so sure.Consultant doctors in England to strike next monthSenior doctors to stage 48-hour walkout, beginning on 25 November, in dispute over pay and pensions.The 4 stages of women’s heart health: Experts present new frameworkNew guidance is intended to help girls and women — and their doctors — recognize four distinct phases in heart health.Opinion: Could long-term AI use lead to isolation? We need to find out — but researchers need better access to data“What we don’t know is whether people are disconnecting from one another, gradually, over months of interacting with chatbots,” researchers write.Opinion: How bad is healthy supposed to feel?“We shouldn't confuse illness and the hardships that come with living,” writes family nurse practitioner Kirsten Balin.STAT+: Moderna CEO on what’s next after success in cancer vaccineModerna's CEO Stéphane Bancel on what's next after the recent success in cancer vaccine, and how that impacts the company's business strategy.STAT+: NIH’s new vaccine injury center has broad goals beyond RFK Jr.’s focus on shotsThe center will study the long-term impact of infections, in addition to RFK Jr.'s focus on vaccines.Is 'ferritin face' a real thing - and can you really spot low iron from looks?Videos in which people claim to spot the signs of low iron have attracted millions of views online.Hospital deemed 'dangerous' and 'dreadful' online claims to be among safest in the countryGrange University Hospital has faced criticism over long delays, overcrowding and staff shortages.#ESMO26: Akeso details ivonescimab's biliary cancer success, drawing Keytruda comparisonsMADRID — Akeso on Sunday spelled out by how much its Summit Therapeutics-partnered PD-1xVEGF bispecific improved survival in a late-stage, China-only biliary tract cancer study, in one of its early moves to find success beyond ...STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcaseAstraZeneca has seen major momentum in oncology in recent years. It got a big showcase at Europe's top cancer conference.#ESMO26: Merck and Moderna's cancer vaccine data were 'a triumph of science.' And now, the work beginsMADRID — In a testament to clinicians’ interest in Merck and Moderna’s personalized cancer vaccine data at this year’s European Society for Medical Oncology conference, the presidential symposium, which can seat thousands of…#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trialMADRID — Roche’s next-gen KRAS G12C inhibitor cut the risk of death by 44% in previously treated mutant non-small cell lung cancer in a head-to-head trial against drugs with the same target from Amgen and Bristol ...#ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tagrisso's life in lung cancerMADRID — AstraZeneca said Sunday it might have found a way for patients with mutant non-small cell lung cancer to keep taking Tagrisso even after they have become resistant to the EGFR-targeting tyrosine kinase inhibitor. In ...The debating club that helped shape NHS architect Aneurin Bevan's drive for powerHow a group of young radicals helped set Aneurin Bevan on the path to founding the NHS.Health board still paying for research despite criticism over patient benefitBetsi Cadwaladr health board was due to pay Bangor University £110,686 for two researchers.#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activityMADRID — Pfizer is moving past its late-stage loss in non-small cell lung cancer, pointing to a post-hoc analysis of earlier-line patients who appear to benefit. Also on Sunday, BioNTech and Bristol Myers Squibb touted ...STAT+: After a cancer vaccine’s first success, the race is on to expand the impactMADRID — With the first pivotal trial showing a customized mRNA treatment improved outcomes for cancer patients presented here this weekend, the conversation has already turned to how melanoma specialists…My 93-year-old mother waited 10 hours on the floor for an ambulanceGraham Anthony says his mum Margaret Owen was asking for help "and sometimes screaming in pain".The ESMO presentation everyone’s been waiting forModerna and Merck's 'presidential' presentation, and other news from Day 2 of the European Society for Medical Oncology meeting in Madrid.#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancerMADRID — It's been estimated that almost 40,000 delegates will be attending this year's ESMO congress over five days in Madrid. And on Saturday, they have new data to review from AstraZeneca, Eli Lilly and Bayer. ...#ESMO26: Amgen's Imdelltra regimen more than halves risk of death in Phase 3 lung cancer trialMADRID — Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi slashed the chances of dying by 58% versus Imfinzi alone in the first-line maintenance setting in certain small cell lung cancer patients, breezing past the benchmark…Opinion: Christina Applegate puts a face on one of the most consequential challenges in neurology“The goal is not simply to diagnose MS faster. It is to get the diagnosis right,” writes Bruce Bebo.Opinion: STAT readers on Elizabeth Holmes, cancer screening, and more“Even if Theranos had a functioning testing machine, the economic model on which is was based would result in failure,” writes a STAT reader.Cancer vaccine data from #ESMO26; Treasury proposal could curb China investment; and moreHello from Madrid, and welcome back to Endpoints Weekly! I’m at #ESMO26 with my colleagues Ayisha Sharma and Reynald Castaneda. The most anticipated readout from this year’s conference was Merck and Moderna’s Phase 3 study ...Windward Bio files for Nasdaq IPO to fund China-derived assets and in-house R&DA 2-year-old European biotech with two clinical-stage assets from China is the latest to attempt an initial public offering in the US. Basel-based Windward Bio submitted its cards for a Nasdaq ...Fitness became an addiction that left me anxious and sleep deprivedWayne Davies was left "constantly worrying" about race times, comparing himself to other runners on social media.How Does the Quality of the U.S. Health System Compare to Other Countries?This chart collection compares the United States and other similarly large and wealthy nations across various measures of care quality to show how the U.S. stacks up against its peers and how that has changed over time.Americans’ Challenges with Health Care CostsThis data note summarizes recent KFF polling on Americans’ experiences with health care costs, which factor into decisions about insurance coverage and care seeking and consistently ranks as a top financial worry for adults and…GP says she was forced out of job after raising concerns about gender treatmentThe doctor says she faced a brutal investigation after she passed on complaints brought to her by other doctors.STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived earlyIn data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.STAT+: Diabetes association says ‘threat’ preceded members’ ejections but admits policies were unclearThe American Diabetes Association has issued two explanations, two reviews and an apology over its June convention. A Friday report adds new twists.STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trialWhere should the safety bar be for studies investigating CAR-T therapies for autoimmune conditions?STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis findsMost new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.Q&A: Bristol Myers' Lynelle Hoch on autoimmune CAR-T safety challengesBristol Myers Squibb is facing one problem after another with its autoimmune CAR-T therapy program. The company says it has figured out the cause of the safety signal in a lupus trial ...What We Know about Trump’s $500 ACA Checks and the User Fees Funding ThemThis analysis examines the $500 checks that the Trump administration is sending to some Affordable Care Act Marketplace enrollees and the user fees that are paying for them. The checks are going to about 1 million enrollees in…Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trialsAn MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.Opinion: It took me 13 years to be diagnosed with MS. Christina Applegate’s misdiagnosis doesn’t surprise me“I felt Christina Applegate’s disappointment as if it were my own — because not long ago, it was,” writes Lindsay Karp.STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.Remembering STAT’s Helen BranswellThis week on the “The Readout LOUD” podcast, we remember our beloved colleague Helen Branswell, who died last week. We speak with colleagues, family, and public health leaders about her…STAT+: Tango builds on Revolution Medicines’ pancreatic cancer successAs the ESMO conference kicks off, Tango's pancreatic cancer combination shows striking promise and detailed data on Moderna and Merck's cancer vaccine is released early.Lycia's $318M IPO; Merck sac-TMT trial stopped earlyPlus news about Hexagon Bio, Mineralys Therapeutics and Arbor Biotechnologies. Lycia prices $317.5 million IPO: Lycia Therapeutics, a company founded by Nobel Prize winner Carolyn Bertozzi, is pricing its initial public ...Roche taps Zymeworks in up to $813M deal for preclinical T cell engagerAnother day, another Roche deal. The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell engager (TCE) that could go head-to-head with Amgen’s Imdelltra. Zymeworks ...Anxiety builds over Medicaid work requirementsAs a Boston judge heard a challenge to Medicaid work requirements, state Medicaid directors gathered in Maryland to figure out how to implement those sweeping changes.Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pauseA patient has died in a Bristol Myers Squibb study of autoimmune CAR-T, the same technology that was called into question this summer when both Bristol Myers and Novartis paused similar programs. The patient, who ...STAT+: Treasury proposes major restrictions to U.S. investment in Chinese biotech sectorA new Treasury Department proposal would restrict U.S. investments in Chinese biotechs, but still allows licensing deals.STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and moreA personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to a standard treatmentPathos raises $237M at $3B valuation, signs Bristol Myers neuro partnershipAI-driven biotech Pathos AI has corralled a $237 million Series E at a $3 billion valuation, the New York-based company said on Wednesday. The large fundraise comes in below the $300 million that the biotech ...Post-Hoc Live: Did the US just kill off China biotech deals?Last night, the Treasury Department issued a proposed rule to implement the COINS Act, the 2025 law that governs US investment in sensitive technologies in China and other countries. In a surprise turn, a broad ...Biotech takes a hit as dealmakers take a knee in Q3A chill wind blew through the biopharma industry in the third quarter as the pace of M&;A from the first half of the year cooled down, big upfront licensing deals slackened and venture investing slowed ...STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billionAI drug firm Pathos raises $237 million, a deal that brings together a big Tempus dataset, AI analysis from Pathos, and drug development from BMS.Warp Sciences emerges from stealth, founded by ex-OpenAI science chief and tech veteransWith $215 million in a Series A raise, former OpenAI head of science Kevin Weil has launched a startup in an effort to help pharma companies make the building blocks for new drugs using artificial ...Tango combo clears Rasonque bar, Takeda's Innovent bet gets early returns, plus more from #ESMO26MADRID — While Friday is officially the first day of this year's ESMO congress, some of the anticipation has deflated after keenly awaited data on Moderna and Merck's cancer vaccine were leaked on ...Al Sandrock to step down as Voyager CEO; Insmed adds Paul Hudson to board→ Al Sandrock is calling it quits as CEO of Voyager Therapeutics in the first quarter next year, but he will stay on the board. Chief business and operating officer Robin Swartz, a Sanofi Genzyme ...Star Therapeutics gets $200M to try repeating its Vega, Electra successesStar Therapeutics has collected $200 million to see whether its homegrown research can produce a new pipeline of medicines after prior successes that have been shipped elsewhere. The new capital is essentially a fresh start ...STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancerAn experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.How a targeted drug kept one patient alive 15 years — but failed to save her friendsA lung cancer patient speaks out about her cutting-edge treatment: “Research is big on tracking survival stats, but quality of life for survivors — not so much.”One family’s story of a life-extending medicine for pancreatic cancerBobby Senaha was among the first patients to use daraxonrasib, a new life-extending drug for pancreatic cancer. His wife shares what those extra months meant to his family.Opinion: New Medicare policies will keep important pain relief from some patientsFor some people, simply putting on pants can be excruciatingly painful. New policy will put pain relief out of reach for many, doctor writes.Opinion: Overdose deaths have plunged. We need to know whyThe humbling truth is that forces outside medical care and public health policies must be playing the biggest role in a dramatic drop in opioid overdose deaths, three health experts…STAT reporters react to the new Elizabeth Holmes documentaryIt seems everyone has a hot take on the new Elizabeth Holmes documentary, "You Can See Everything." STAT reporters went to see the film — here's their review.STAT+: State officials scrambling to implement Medicaid work requirements meet up to swap notesWhat state officials scrambling to implement Medicaid work requirements shared behind closed doors at the National Association of Medicaid Directors conference.World first personalised cancer vaccine stops disease returning in major trialThe scientists involved say the results could mark a turning point in cancer treatment, bringing personalised medicine a step closer.Alnylam plans bigger study of RNA drug for Huntington’s diseaseAs with many of the most feared neurological conditions, Huntington’s disease has proven to be a minefield for drug developers. Promising biomarker data didn’t translate into clinical benefits in Roche’s recent study ...STAT+: Alnylam says Huntington’s drug shows promise in early studyIt’s yet to be seen whether Alnylam’s drug will actually slow progression of Huntington’s, but the field is lively.'Wildly unfair that my husband and I pay £4k a year for ADHD treatment'Northern Ireland is the only part of the UK without a formally commissioned, publicly-funded adult service for ADHD.Gilead strikes $1.3B upfront China deal for oral IL-23 drugGilead is going to Shanghai for its latest expansion in the hot inflammation market, dishing out $1.28 billion upfront to PepStar Therapeutics for a Phase 1 asset. The California biopharma is gaining hold of an ...Private care home investors a risk to public sector, regulator saysUS investors are buying up UK care homes - a situation regulators say they are "watching carefully" in case it threatens plans for a National Care Service.STAT+: Gilead to pay $45 million to settle kickback charges filed by Texas attorney generalGilead Sciences agreed to pay $45 million to settle allegations of paying kickbacks that improperly influenced prescriptions paid for by the Texas Medicaid programGive more people weight loss jabs on the NHS, say MPsCurrent plans for 6% of eligible patients to get Mounjaro by 2028 unambitious, say MPs.Haematology centre for cancer patients at risk over 'disgraceful' funds moveThe Department of Health has decided to take back £1.5m from the project, Belfast Trust officials have told a Stormont committee.Treasury proposal would sharply limit US investments in much of China biotechDraft regulations from the Treasury Department would put broad limits on what types of drug and biotech assets that US companies and venture capitalists could invest in and make deals for. The'Difficult decision' to close Samaritans branch after more than 50 years"Sadly, and due to circumstances beyond anyone's control, the difficult decision was reached to close the branch," they charity says.Pfizer details mixed Lyme disease vaccine dataNew data on a closely watched Lyme disease vaccine from Pfizer and Valneva provide details on the near-miss in one of two analyses, as the vaccine's commercial future hangs in the balance. Unveiled Thursday at ...STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trialA Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.Data leak for Merck and Moderna’s therapeutic cancer vaccineMADRID — Results of a Phase 3 trial of Moderna and Merck’s closely watched cancer vaccine were released on Thursday, after the data were leaked earlier in the day. The therapeutic vaccine, named intismeran autogene, cut ...STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectationsAbbVie's lutikizumab, an experimental therapy for a chronic skin condition, succeeded in a late-stage trial but missed market expectations.STAT+: Nutrition experts press White House to release ultra-processed food definitionMAHA allies and nutrition experts want the Trump administration to act on ultra-processed foods before the elections.Top MAHA adviser Calley Means resigns from White House days ahead of midtermsThe surprising departure comes just before an election that may serve as a referendum on the MAHA movement.Roche says it will help patients who are 'anxiously awaiting' its new breast cancer drugRoche is gearing up for a major launch in the shape of its breast cancer pill giredestrant, and according to Teresa Graham, head of the company’s pharma unit, patients are clamoring to get hold of ...STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?Rumors are swirling that the Treasury Department this week is going to propose a rule that restricts U.S. investment in the Chinese biotech sector.American Medical Association CEO talks regulating AI careAs we get closer to autonomous, AI-driven medical care becoming a reality, regulators are racing to catch up. The FDA in August released a discussion paper with ideas about how ...A hepatitis B hold lifted and drug tabled; Ultomiris' accelerated approvalPlus news about Biohaven, Arcus Biosciences and a Boehringer Ingelheim and Microsoft collaboration. Hold on Arbutus drug lifted: It’s been a long, tough road for Arbutus Biopharma. The company hasSTAT+: Crackdowns loom, from China to New YorkSpeaking on the economy, the vice president told a crowd in Ohio that, “You don’t turn the Titanic around overnight.” Send news tips and bad metaphors to John.Wilkerson@statnews.com or John_Wilkerson.07…AbbVie notches Phase 3 win in painful skin condition, FDA filing likely next yearAbbVie unwrapped a Phase 3 success on Thursday for an experimental drug designed to treat a debilitating skin disease. In the trial, AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response ...Sanofi's new German site; radioisotope deals from Northstar and TelixPlus more from Baxter and United Therapeutics. Sanofi starts construction of an insulin factory: Sanofi has broken ground on a new 36,000-square-meter manufacturing facility at its site in Frankfurt, which ...Assessing Ability to Work: How Historical SNAP Processes May Vary from MedicaidIn light of the uncertainty surrounding how states will verify the Medicaid medical frailty exclusion, this issue brief describes how the Supplemental Nutrition Assistance Program (SNAP) has handled similar administrative…Big trials push beyond obesity to see if GLP-1s can quell alcohol, drug cravingsFor nearly as long as they've been approved for diabetes and weight loss, GLP-1 drugs have captured the public imagination as a possible solution to diseases far beyond metabolic disorders. That potential is now inching ...STAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and moreU.S. is poised to issue a proposed rule that would subject outbound licensing deals with Chinese biotech companies to additional scrutinySTAT+: What to expect from the Moderna-Merck cancer vaccine data revealThe Moderna-Merck cancer vaccine data reveal is days away. Here's what to expect.How Much is Health Spending Expected to Grow?This chart collection explores how much health spending is expected to grow in the coming years, with a look at growth in prescription drug spending, out-of-pocket spending, and related trends.STAT+: FDA has finalized its guidance on apps related to drugsIn this edition of STAT Health Tech: FDA's guidance on prescription drug use-related software, and telehealth pushing GLP-1s for addiction.Healthcare industry weighs in on evidence standards for generative AI medical devicesHow much evidence should the FDA require before it authorizes a generative AI-enabled medical device? The question was a point of contention among healthcare lobbying organizations and tech companies, who weighed in as the FDA ...Health insurance premiums jump 9%, and more Americans don’t have access to coverageWorking-age U.S. adults without health insurance rose in 2026. Half of all uninsured people did not seek needed care because of cost concerns, according to a new survey.Redesign Health merges with ARC Global in $2B deal to help hospitals build startupsHealth tech venture firm Redesign Health is merging with ARC Global, the innovation arm of Sheba Medical Center, to help hospitals in different countries develop and sell software. The new company will combine the two ...Recently Released KFF Poll Shows Uncertainty Over Established Safety of COVID-19 Vaccines During Pregnancy – The MonitorKFF’s recently released Tracking Poll finds that public confidence in the safety of COVID-19 vaccines for use during pregnancy has fallen, and many are uncertain about a false claim linking the vaccines with higher risk of…Georgiamune sells solid tumor drug to Italy's Menarini for up to $1.1BA small Maryland biotech is shipping a preclinical cancer drug to a family-owned Italian pharma in a deal worth up to $1.1 billion if all goes according to plan, the companies exclusively told Endpoints News. ...First human case of Shamonda virus detected in France, officials sayThe disease, which usually affects cattle, has been identified in a patient who died in early October.Roche talks up Phase 3 success rate as it unveils pipeline cutsWhere other European pharmas — notably Novartis, Novo and AstraZeneca — have suffered huge late-stage clinical failures this summer, Roche is feeling rather smug. CEO Thomas Schinecker said ...MI5 spied on Nye Bevan for more than 20 years, newly released files showHe came to its attention in the 1930s when he was considered a left-wing firebrand.2026 Employer Health Benefits SurveyThis is the 28th Employer Health Benefits Survey (EHBS) and reflects employer-sponsored health benefits in 2026. As in years past, the survey examines trends in employer coverage, including premiums, employee contributions…Workers Now Pay $7,471 on Average Annually for Family Health Coverage, Up 9% or $621 from 2025, Benchmark Employer Health Benefits Survey FindsWorkers are paying on average $7,471 annually toward the premiums for employer-sponsored family health benefits this year, which is up 9%, or $621, from 2025, per KFF’s annual benchmark health benefits survey of large and small…STAT+: Workers are paying 9% more for family health coverage this year, a higher jump than in the recent pastA KFF survey finds that rising healthcare costs are squeezing both employers and workers.Premiums and Worker Contributions Among Workers Covered by Employer-Sponsored Coverage, 1999-2026Since 1999, the Employer Health Benefits Survey has documented trends in employer-sponsored health insurance. Every year, private and non-federal public employers with 10 or more employees complete the survey.Opinion: The inherited disease my family called ‘it’ had a name, which changed everythingFor 50 years, doctors shrugged about the disease running through Miranda Pappas’ family. Then she discovered something.Opinion: What I got wrong about the Affordable Care Act — and how to fix it“The big mistake, ironically, was the ACA’s lack of focus on affordability,” writes Dana Goldman.STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addictionAs telehealth promotes GLP-1s for addiction, experts worry about fragmented care, and exposing patients to unknown risks.Rezera files for IPO to back NLRP3 work in peripheral artery diseaseRezera, the biotech that rebranded from NodThera earlier this year, has entered the queue for an initial public offering to bolster its decade-long NLRP3 efforts. The biotech submitted its pitch Wednesday ...China biotech RiboX reveals first data of circular RNA therapies in peopleBiotech investors and pharma companies have poured billions into three Boston-region startups competing to develop a next-generation version of mRNA technology that could make for more durable and potent therapies. But now a…'Betrayed by my body': The taboo health issue women are talking about on social mediaWomen are sharing their experiences with chronic urinary tract infections on social media in an effort to break the stigma surrounding UTIs.Diabetes and ADHD drugs to be tested on Alzheimer's patients in new studyDrugs will be tested simultaneously, which it's hoped will speed up the process of finding new treatments for this common type of dementia.Daughter of woman killed by partner 'refuses to be another victim'Keeley McKee's mother Leanne was killed by her partner in 2003, weeks before the couple were due to marry.STAT+: CMS extends fraud crackdown to New York’s adult day care programCMS is cracking down on adult day cares in New York, part of a broader focus on alleged health care frauds.Pope does not need further treatment after lung cancer surgeryTest results have confirmed his diagnosis as a lung adenocarcinoma that was localised.STAT+: Another diabetes association leader is out while review continuesAn endocrinologist who had long served in the American Diabetes Association's leadership is out without explanation.Treasury expected to be harder on China biotech deals in new rulesThe pharma industry is bracing for a more stringent assessment of China deals from the Treasury Department, despite months of work to escape a harsh clampdown on buying new assets there. Endpoints News spoke with ...STAT+: What’s the deal with Isomorphic Labs?In this edition of STAT's AI Prognosis: What does Isomorphic Labs' high valuation say about AI's role in drug development, and the debate around AI and cost of care.The Future of CDC HIV Prevention Funding for Community OrganizationsFollowing reports that CDC is ending Community Based Organization (CBO) funding for HIV prevention, this analysis provides a snapshot of where, to whom, and at what level these community grants were distributed in the past grant…Samsung Bio union to contest court ruling blocking worker strikesSamsung Biologics may have won court approval to block upcoming worker strikes, but the company's labor union plans to appeal the decision and take further action. The labor group for the contract developer and manufacturer ...5 takeaways from Endpoints' AI Day: agents, AI slop, biosecurityIn 2024, I started Endpoints News’ flagship AI event because I didn’t see anything like it. Biopharma conferences scratched the surface with a stray AI panel. Machine-learning events like NeurIPS didn't gather the whole drug ...CSL hires ViiV CEO Deborah Waterhouse after three decades at GSKDeborah Waterhouse is moving on from a 30-year career at GSK, departing as CEO of the UK pharma's HIV specialist ViiV Healthcare. Waterhouse will take on the CEO post at CSL onAlcon and OpenAI make acquisitions; Tezspire's latest Phase 3 winAlcon acquires Neurotech: The Swiss eye specialist paid $550 million upfront to acquire Neurotech Pharmaceuticals and could make additional payments if certain milestones are met. Alcon gains hold of an FDA-approved ...Roivant's autoimmune drug succeeds in two pivotal trials, setting up 2027 filingRoivant Sciences on Wednesday checked off another milestone in its attempt to build a franchise drug in autoimmune diseases. The biotech said two trials for brepocitinib, which won its first approval earlier ...STAT+: GSK picks up hep B drug approvalGSK has won FDA approval for its hepatitis B drug, which extended functional cures to far more patients than previous methods.Midterm Election Update: Medicaid ChangesMajor federal changes to Medicaid eligibility and financing from the 2025 reconciliation law are coming, including new work requirements that will affect millions of Medicaid enrollees. KFF’s fact sheet provides an overview of…STAT+: Pharmalittle: We’re reading about Mark Cuban eyeing rare disease drugs, a ketamine gold rush, and moreMark Cuban has a new vision for his company Cost Plus Drugs: shake up the business of custom-made rare disease medicinesA Closer Look at State Directed Payments for Nursing Home ServicesBuilding on previous analysis of state directed payments (SDPs), this issue brief takes a closer look at SDPs for nursing home services.STAT+: Roivant says closely watched immune drug succeeded in new eye diseaseAn immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis.Nigeria identifies travel-related Ebola caseNigeria has confirmed an imported Ebola case tied to the ongoing outbreak centered in the Democratic Republic of the Congo, becoming the fifth country to identify a related infection, health…GSK gets FDA approval for hepatitis B drug that offers functional cureThe approval of GSK and Ionis’ chronic hepatitis B drug bepirovirsen came early, setting it up to eventually reach blockbuster status. But the FDA gave the drug, now branded Hibsago, a'Lessons need learnt' after report into care homes during Covid publishedAn inquiry found that Government failings in care settings allowed the spread of Covid.A counterintuitive way to build trust in measles vaccines and public healthSome experts say public health messaging would be more credible if it focused less on measles deaths and acknowledged that most children survive.Opinion: How knocking on doors can help beat measles — again“As measles outbreaks spread in the U.S., it may be time to learn how other countries get their outbreaks under control,” writes Raj Panjabi.Opinion: Replication is necessary even if scientists do everything right“Committing a Type 1 error does not reflect poorly on the quality of the science done,” writes Mark Louie F. RamosSTAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approvedAfter a quarter century of work, the German biotech Immatics is facing a pivotal moment as it awaits Phase 3 results for its lead candidate in melanoma.STAT+: Mark Cuban wants to crack open the market for rare disease treatmentsMark Cuban's Cost Plus Drugs says it can reduce manufacturing costs for custom rare disease drugs and n-of-1 gene therapies.Lilly’s retatrutide creeps closer to market for sleep apneaExpectations for the launch of Eli Lilly’s triple agonist retatrutide in obesity, due next year, are at fever pitch. But the company is also lining up data in other indications with the aim of eventually ...Tighter rules planned to protect people from cosmetic surgery that goes badly wrongThere will be restrictions on who can carry out procedures and fines for those who flout the law, in England in 2027.STAT+: He’s slashing quality at nursing homes. This state is letting it happenThe Boston Globe Spotlight Team found Eli Mirlis made grim cuts to resident care while steering millions of dollars from his nursing homes’ revenue into a constellation of real estate…Second Labour MP suspended over Covid loan repaymentsPerran Moon, MP for Camborne and Redruth, voluntarily referred himself for investigation.STAT+: State regulators move to seize licenses from nursing home chain that was focus of Boston Globe investigationA Boston Globe investigation found that RegalCare acquired nursing homes across Massachusetts, then gutted the quality of care.New ICER report suggests drug launch prices are outpacing their worthThe median list price of drugs at launch rose 24% from 2022 to 2025, and the net prices of those drugs rose even higher, according to a new report from the Institute for Clinical and ...STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loopholeA bipartisan group of lawmakers is urging the FDA to plug a loophole used to import knockoff retatrutide, an investigational obesity drug made by Eli Lilly.STAT+: Roche continues to look to China for new drugsChina's Hansoh Pharmaceutical Group has announced that it struck a massive deal with Roche to develop a portfolio of antibody-drug conjugates.Why I wish you didn’t want to see Nathan Fielder’s Elizabeth Holmes documentaryA reporter who interviewed Elizabeth Holmes on why society confuses authenticity, honesty, and truth, and how she takes advantage.Government failings allowed Covid 'to spread like wildfire' in care homes, inquiry findsThe sixth report from Covid inquiry criticises the lack of PPE and the way patients were discharged from hospital.An EHR giant backs consumer healthcareEpic last week said it was launching a "prescription marketplace" that would allow physicians and their patients to compare prices for medicines at different pharmacies — all while in the doctor’s ...Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPOPfizer halts Phase 2 autoimmune trial: The study was testing a program called PF-06835375 in the rare autoimmune disorder primary immune thrombocytopenia. The federal clinical trials database noted the halt was ...STAT+: OpenEvidence’s JAMA paper leaves open questionsIn this edition of STAT Health Tech: A new paper in JAMA offers a glimpse into clinicians's use of OpenEvidence, and a look at Isomorphic Labs.STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and moreThe median net price for newly launched medicines, when adjusted for inflation and manufacturer discounts, rose by 35% from 2022 to 2025.Biopharma Sentiment Index | Q3 2026 survey resultsThe latest BPSI shows dramatic improvements in biopharma conditions and a level of optimism not seen in years. It's official: Biopharma is finally in a good mood. For the first time since the four-year downturn ...How voters feel about trans rights and abortion access will soon be put to the testHow do voters feel about trans students participating in school sports teams? Or abortion access? The U.S. is about to find out.STAT+: Dana-Farber, Beth Israel to begin construction of new $1.68 billion cancer hospitalDana-Farber Cancer Institute and Beth Israel Lahey Health are starting work on a $1.68 billion cancer hospital in Boston, marking a new phase in their competition with Mass General Brigham.KFF Polling on Health Information and TrustDrawing on KFF's poll findings, this interactive dashboard tracks the public’s trusted sources for health information, attitudes toward vaccines, and use of news, social media, and AI for health-related information. It provides…KFF Tracking Poll on Health Information and Trust: Fall 2026 Update on Vaccine ViewsThe latest KFF Tracking Poll on Health Information and Trust finds about half of parents mistakenly believe spacing out vaccines is healthier for children, while confidence in many long-standing childhood vaccines is high across…Covid failings in care homes: What the inquiry saysFrom the shocking lack of PPE to restrictions on visitors - the key points from the sixth Covid inquiry report.Exclusive: Astellas partners with Boston ‘miniproteins’ startupChris Bahl believes AI can help make tiny proteins capable of doing things that bigger and more traditional proteins like antibodies struggle to do. And now the Japanese drugmaker Astellas is buying into his vision ...'I started ketamine at 14 and needed nappies at 22'For the last two years Megan has been in agony and unable to stand straight because of her ketamine use.Rapport says drug it licensed from J&J clears Phase 2 bipolar mania studyRapport Therapeutics said Tuesday its investigational oral drug that dials down the effect of AMPA receptors has cleared a mid-stage trial in bipolar mania, paving the way for registrational studies slated to start next year. ...STAT+: Launch prices for new medicines dipped slightly last year but remain high, analysis findsThe median net price for 202 newly launched medicines rose by 35%, to $257,000 last year from $173,000 in 2022.Building the AI HospitalWalk into the emergency room at Israel’s largest hospital and the first clinician to take your history may be an AI avatar — with a physician signing off on every recommendation. Israel’s Sheba Medical Center is building what…Opinion: Resident physicians may lose some of their most important work hour protections“It is important to create barriers between high intensity shifts with physical, intellectual, and emotional burden to avoid burnout” in residents, writes Arifeen Rahman.STAT+: The key health care ballot measures we’re watching in the midtermsState fights over issues like transgender rights and Medicaid offer clues to where Americans stand on contentious health matters.Can a simple photo of your face reveal how ill you are?AI may help doctors judge how ill a patient is using a single photograph of their face, say US researchers.POV: Your girls' PE lesson gets a glow upCan activities like yoga, dance and fitness encourage more girls to enjoy sport?'I started ketamine at 14 and needed nappies at 22' - the rise of young people going to rehabFor the last two years Megan has been in agony and unable to stand straight because of her ketamine use.Former MIT professor David Sabatini awarded $6M in defamation caseA Massachusetts jury awarded $6 million in damages to prominent biologist David Sabatini, years after sexual harassment allegations led to his ouster from MIT. Roughly five years ago, Sabatini brought theAntheia gets $80M conditional DoD loan to onshore to the USBiosynthesis manufacturer Antheia has won a conditional loan of $80 million from the US Department of Defense to help boost the domestic production of generic drugs. "Over time, we aim to manufacture Antheia's full pipeline ...Trump orders creation of NIH division, task force on women’s healthMelania Trump says a new research and policy initiative will set “a new standard for women’s health.”Opinion: I was a Theranos whistleblower. In ‘You Can See Everything,’ Elizabeth Holmes is still lyingA more accurate name would be “You Can See Everything That We Chose To Point The Camera At,”Theranos whistleblower Tyler Shultz writes.#ESMO26 regular abstracts featuring Zai Lab, GSK, Merck and moreThe last time the ESMO congress was in Madrid, a presentation on first-line data in bladder cancer drew a rapturous standing ovation. Contenders that might draw the same reception include hotly anticipated ...Medicaid State Fact SheetsMedicaid State Fact Sheets Medicaid and CHIP provide health and long-term care coverage to millions of low-income children and adults in the United States. The programs are jointly financed by the federal government and states…STAT+: The umpires getting rich off surprise medical bills, and MLB job lockWe dig into trust, prices, and a bit of baseball in this week's Health Care Inc. newsletter.Gilead’s pill posts stronger colitis remission rates than EntyvioGilead Sciences is to start late-stage trials of its oral α4β7 inhibitor in ulcerative colitis next year, after data from a Phase 2 dose-finding trial suggested that the drug looked better than rival products. After ...EyePoint's Phase 3 failure; Lilly's China drug delivery dealPlus news about Longwood's next fund and Ryzumvi's label expansion. EyePoint drug fails, biotech halves staff: The Watertown, MA-based biotech is letting go of 53% of its positions after its experimental ...STAT+: China moves to restrict foreign biotech acquisitionsChina is proposing new restrictions on foreign acquisitions of critical biopharma technologies, as the country seeks to retain control over its burgeoning drug development industry.Merck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3BGermany's Merck KGaA agreed to buy UK drug developer Silence Therapeutics for $1.3 billion, building out its work in rare and specialty diseases using genetic medicines. Silence is developing the siRNA drug divesiran, which is ...Two former Republican lawmakers say the GOP’s vaccine position is a liabilityThe Republican party’s confusing messaging on vaccines is going to hurt candidates in the midterms, two former GOP congressmen argue.STAT+: Pharmalittle: We’re reading about Roche investments in Germany, a Gilead bowel disease drug, and moreRoche is reviewing all future investments in Germany over health care cost-cutting policies, with a top executive citing a loss of trustSanofi taps new startup ScionxBio for long-acting RNAScionxBio has inked a deal with French drugmaker Sanofi — its first partnership since splitting from parent company Eleven Therapeutics a few months ago. Under the agreement, ScionxBio will screen Sanofi’s mRNA candidates through…AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trialAbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday. The new product is codenamed ABBV-466 and combines…Charity offers to meet James McClean over therapy commentsMichael Lynch, from Men's Action Network (MAN) offered to meet the Derry City footballer James McClean.Roche does $400M upfront, $15B deal with China's HansohRoche is going all in on Chinese drug discovery and development. The Swiss pharma has inked one of the largest cross-border collaborations of the year, promising $400 million upfront and potentially $15 billion in biobucks ...Disc Medicine reports 'sun allergy' drug hits Phase 3 home runDisc Medicine’s treatment for a rare disease that makes sun exposure painful succeeded on all endpoints in a Phase 3 study. The result sets the company on a path to redemption after the FDA unexpectedly ...TriGemX Bio is going public through SPAC to get its migraine prospect to marketThe stock market will soon welcome another drug developer through a backdoor route that has been fallen out of favor now that traditional IPOs are flowing. TriGemX Bio, formerly known as Kallyope, is going public ...Veradermics' oral Rogaine wins again at growing hair in late-stage trialVeradermics is taking another victory lap with its oral twist on minoxidil, commonly known as Rogaine. The Connecticut biotech said VDPHL01, its extended-release version of the decades-old hair-regrowth drug, cleared all primary…STAT+: Gilead’s IBS drug eliminated symptoms for patients, mid-stage study findsAn oral treatment from Gilead Sciences eliminated the symptoms experienced by patients with a type of inflammatory bowel disease, according to mid-stage study results reported Monday.Opinion: Measles is back — and becoming a midterm liability for Republicans“Silence on vaccines is becoming a dealbreaker for voters who would otherwise vote Republican,” write physicians and former GOP Reps. Larry Buchson and Michael Burgess.Opinion: My mother killed herself. I wish assisted suicide had been an option“Sometimes mental illness is terminal,” Torie Bosch writes in a personal essay about medical aid in dying for psychiatric reasons.STAT+: Does Isomorphic Labs have what it takes to revolutionize drugmaking?Isomorphic Labs wants to turn its technology into an engine for new medicines. The question now is whether — and how — it can deliver on that promise.STAT+: How the No Surprises Act’s nonprofit arbitrators are operating like ‘mini gods’ and getting rich doing itA STAT investigation found that several nonprofits are raking in massive sums by acting as arbitrators in a program that helps protect patients from surprise medical bills.STAT+: Top immunology association divided over $8.4-billion California ballot measure to fund the field, emails showInternal emails obtained by STAT show that the American Association of Immunologists is sharply divided over California's Proposition 38, even though it would provide $8.4 billion in taxpayer dollars for…Nouscom raises $135M in Series D for lead cancer vaccineClinical-stage cancer biotech Nouscom has raised $135 million in an oversubscribed Series D funding round to take its lead vaccine through to a Phase 2 study. “We're super excited because there is the potential of ...Rural lives cannot be an 'afterthought', healthcare campaigners sayCampaigners warn that rural communities face being cut off from vital hospital services.NHS leaders say maternity care organisation is 'not fit for purpose'The NHS Alliance said "difficult decisions" lie ahead and some maternity services may have to be consolidated.Companies exploiting welfare system by using residents as 'cash cows,' BBC findsAgents try to attract people on housing benefit by using social media videos that offer free rooms and holidays.STAT+: Cambridge scientist David Sabatini speaks out after courtroom victory: ‘The hardest years of my life’"The hardest years of my life," is how Cambridge scientist David Sabatini describes the time since his downfall from MIT.Inside Chicago's battle against the synthetic drugs flooding the USA new wave of synthetic drugs is sweeping across the United States, raising fear of a worsening drug crisis. The BBC's Quentin Sommerville reports from the frontlines in South Side, Chicago, where communities are battling the…NHS faces more challenging winter than normal, health secretary warnsYvette Cooper has announced £140m investment in England's urgent care system, after summer heatwaves piled pressure on the NHS.Health workers run out of patience with Stormont budget delayThe practical impact of Northern Ireland's budget delay seemed relatively muted until earlier this week when hospital doctors announced two strikes.Pope to be discharged days after lung cancer surgeryThe pontiff will give the traditional Angelus prayer and blessing in St Peter's Square on Sunday.A search for ‘the statin of Alzheimer’s’; Arrowhead injectable lowers tau; and moreWelcome back to another edition of Endpoints Weekly. Thanks to everyone who came out to our AI Day event this week in New York City! Hosted by senior biopharma correspondent Andrew Dunn, AI Day was ...STAT+: Jury rules in favor of ousted Cambridge scientist David Sabatini, with $6 million in damages to be awardedA jury awarded $6 million in damages to scientist David Sabatini, whose career imploded after he was accused by a much younger colleague of inappropriate sexual conduct in his lab.Status of State Medicaid Expansion DecisionsThis page displays an interactive map of the current status of state decisions on the Affordable Care Act's Medicaid expansion. Additional Medicaid expansion resources are listed (with links) below the map.Q&A: Sanofi's new research chief on AI, R&D failure rates and dealmakingPaulo Fontoura took over as Sanofi’s global head of R&;D in September after 16 years at Roche and a recent stint at AI drug discovery startup Xaira Therapeutics. Ahead of Sanofi’s Oct. 30 earnings, Endpoints ...Hospitals’ next lucrative bet — longevity clinicsOn this week's “The Readout LOUD,” STAT's biotech podcast, we discuss the booming industry of longevity health.Novartis scraps Fabhalta study in lupus nephritisNovartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a federal clinical trials database. Fabhalta, also known as iptacopan, is a key part of Novartis' portfolio. It…Russian man linked to deadly London hospitals hack arrestedThe 28-year-old detained by German police is accused of being part of the cyber-crime gang that hacked blood-test firm Synnovis in 2024.China pursues export ban on some biotech platformsThe Chinese Ministry of Commerce is clamping down on the kinds of deals domestic companies can make, but the free-flowing licensing of drugs appears to be intact. Government officials are looking atFDA considers interim access for compounded peptides; Enspryng's label expansionPlus news about Microbiotica, Cyrano Therapeutics and Opus Genetics. HHS and FDA submit peptide policy for review: An “interim access policy for compounding using certain peptides” is awaiting regulatory review at the White House…Policy Tracker: Exceptions to State Abortion Bans and Early Gestational LimitsThis policy tracker documents exceptions in each state’s most restrictive gestational limit or total ban.Covid vaccine compensation scheme set for overhaul after Inquiry criticismMinisters promise to reform the scheme that provides financial support for those injured or bereaved by vaccines in the UK.CHMP endorses Eli Lilly’s GLP-1 pill and three other new drugsEli Lilly secured EU regulatory backing for its oral GLP-1 pill orforglipron on Friday as it looks to catch up with competitor Novo’s Wegovy pill. The European Medicines Agency’s human medicines committee (CHMP)Pope pictured for first time since surgery and cancer diagnosisThe pontiff was diagnosed with lung cancer after having surgery at Rome's Gemelli Hospital on Tuesday.Lilly interested in ibogaine investments, its neuro leader saysEli Lilly is interested in R&;D efforts to “improve the profile of ibogaine,” the pharma giant’s neuroscience president said at a psychedelics conference Thursday. Carole Ho, who joined the company last year from Denali…STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.STAT+: Pharmalittle: We’re reading about an HHS peptide push, Trump’s pharma stock holdings, and moreThe Trump administration is proceeding with a plan to allow compounding pharmacies to produce certain peptidesSTAT+: RevMed’s pancreatic cancer drug nears European approvalFollowing a green light from the FDA, European regulators have now recommended the approval of Revolution Medicines' Rasonque for pancreatic cancer.Here's how many clinicians are using AI to answer their medical questionsNew research illustrates the rapid rise of clinicians’ use of AI to answer medical questions despite little evidence of how it affects decision-making or patient outcomes. Researchers studied usage data from OpenEvidence, an AI…What to read before you go see that new documentary on Elizabeth HolmesAhead of "You Can See Everything" hitting theaters, let's rewind the last decade and review some of the most significant news tied to Elizabeth Holmes, who was convicted in 2022…Ex-Genentech scientist joins Ira Mellman at Medici; Intellia poaches CMO from Scholar Rock→ More former Genentech leaders are finding a new home. Lélia Delamarre posted on LinkedIn that she’s leading R&;D at ARCH-backed cancer biotech Medici Therapeutics, one of this year’sEstuary debuts with $103M to develop kidney disease gene therapiesEstuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most common type of inherited kidney disease. The company’s cash comes from a ...City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi fieldCity Therapeutics will be the 26th biotech to complete an initial public offering in 2026 when it begins trading Friday morning, adding to a boisterous rebound in industry listings. The Kendall Square-based drug developer priced…School's plan to use toilet chaperones puts pupils at risk, says campaignerSome pupils will have to be escorted to the toilet over vandalism and attendance problems.Opinion: I thought I knew why patients stopped taking their medicine. I was wrongPatients can understand that medication is necessary and still struggle with what taking it means.Opinion: Is Milton Friedman to blame for America’s health care woes?Health policy experts John McDonough and Stuart Butler debate where the U.S. medical system went wrong — and how to fix it.STAT+: Coerced sex or a jealous ex? Jury weighs dueling accounts of star scientist David Sabatini’s downfallWas molecular biologist David Sabatini a manipulative mentor who coerced a younger colleague into sex? Or was he the victim of a spurned former lover?STAT+: In DOGE’s aftermath, federal health workers bristle at new performance reviewsChanges to the annual performance review process are the latest flashpoint in tensions between federal workers across the Department of Health and Human Services and the Trump administration, federal employees…Same-day test helps doctors detect hidden infections in critically ill childrenMetagenomics offers a new way of detecting infections in intensive care patients.Trump administration advances plan for peptide drugs favored by RFK Jr.U.S. health officials are moving ahead with a plan to allow specialty pharmacies to produce certain peptides, a class of largely unregulated injections favored by health secretary Robert F. Kennedy…Green Card Processing Backlogs for Refugees and Asylees Could Have Implications for Health Coverage and CareThis data note highlights changes in green card (I-485) application processing for refugees and asylees between fiscal year (FY) 2021 and FY2025, as well as across the first three quarters of FY2025 to FY2026 (since FY2026 data…Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine successStephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA vaccines to target tumors.CDC page supporting Covid vaccines for pregnancy went darkThe CDC briefly published a webpage that maintained unequivocal support for Covid-19 vaccines in people preparing to have a baby, but it now redirects elsewhere on the CDC's website, following online backlash from some vaccine ...Medicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by StateSection 1115 Medicaid waivers can allow states to test new approaches in Medicaid that differ from what is required by federal law. This page tracks approved and pending waiver provisions (including expansions and restrictions)…The Trump administration is doubling down on health care fraud investigationsAt the STAT Summit, the Department of Justice offered up a warning for health care executives: Don’t be another Theranos.Virginia leads in winning investments as drugmakers onshore to the USThe state of Virginia is emerging as an early winner as President Donald Trump prods drugmakers to increase their manufacturing investments in the US, securing at least $12.6 billion through commitments from three of the ...Mass. lawmaker Auchincloss favors boosting U.S. biotech over targeting ChinaRep. Jake Auchincloss (D-Mass.) has some advice for fellow lawmakers: unapologetically support the biotech industry.How Is The Federal Government Counting Measles Deaths?Recently Secretary of HHS Robert F. Kennedy, Jr., changed how the federal government tracks deaths in its official measles tally, after Pennsylvania reported four deaths. This Policy Watch reviews the two roles, strengths, and…STAT+: Former FDA commissioners Califf, Gottlieb, Sharpless lay into current HHS leadershipFormer FDA commissioners Rob Califf (Obama and Biden administrations), Scott Gottlieb, and Ned Sharpless (both from the first Trump administration) criticized the officials who ran the agency during a massive…STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancerVerastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…AstraZeneca does AI deal with insitro; inVIOs' Phase 1 success in solid tumorsPlus news about ImmunityBio, Modus Therapeutics and Hyperway Pharmaceutical. AstraZeneca strikes AI drug discovery deal with insitro: The pharma giant will pay the California-based company $40 million upfront. In return…After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forwardA schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.NorthStar's China CRO deal; Lonza details midterm guidancePlus more about Triastek, Scinai and HydRegen. NorthStar inks deal with Chinese CRO: Radioisotope maker NorthStar Medical Technologies has secured a partnership with Beijing-based contract research organization Quarkmed. Quarkmed…Trans people should use hospital spaces according to biological sex, NHS England saysNew guidance says trans patients should be cared for on single-sex hospital wards or bays that align with their biological sex.Calls to improve endometriosis awareness in the workplaceJune says better workplace understanding of the impact of endometriosis might have helped her daughter.Osivax pivots to combo approach after flu jab fails in Phase 2bOsivax’s lead flu vaccine has flopped in a mid-stage trial. But the French biotech still holds out hope for the program, and plans to combine it with existing flu shots. The Phase 2b trial aimed ...San Francisco's pulse on health AII flew to San Francisco yesterday to take part in Rock Health’s annual summit. It’s been about half a year since I last visited, so the event served as a good gut check of where ...OrbiMed raises $3B in new life sciences funds, including $1B+ for AsiaOrbiMed, one of the biggest life science investors in the world, has raised $3 billion across two new funds. OrbiMed’s 10th private equity fund in its flagship series put together “over $1.9 billion” to invest ...STAT+: Pharmalittle: We’re reading about former FDA head calling DOGE a ‘disaster,’ an AstraZeneca AI deal, and moreThree former FDA chiefs lit into the Trump administration, criticizing the now former FDA officials who oversaw a massive staff exodusBenchling’s Science Foundries put teams of AI agents in charge of whole R&D workflowsWith Science Foundries, launched today, the R&;D software company moves from helping scientists with individual tasks to managing entire scientific processes with teams of AI agents. The launch builds on a series of products…STAT+: ‘AI sandboxes’ are all the rage. Advocates scramble to control their futureIn this edition of STAT's Health Tech newsletter: The groups vying to shape regulations that'd govern state AI sandboxes, and more.AI will force doctors to focus on clinical reasoning, experts sayThe growing use of AI tools is changing the skills doctors need to practice medicine, experts said during a panel at an Endpoints News event on Wednesday. Doctors no longer need to memorize as many ...Kenya reports second Ebola caseKenya reports a second Ebola case. Meanwhile, the situation in Congo is still quite dire. Authorities have confirmed more than 4,000 deaths and 9,000 cases as officials have struggled to…Hospital doctors to strike as pay dispute continuesThe British Medical Association says hospital doctors in Northern Ireland plan to strike in November.Vanda’s social anxiety drug flunks Phase 3 trial in female patientsVanda Pharmaceuticals said Wednesday it is putting its social anxiety disorder program on hold following a late-stage trial failure. The biotech’s drug, called VQW-765, missed the primary endpoint in a Phase ...Paul Stoffels to bring Galapagos’ cell therapies back to lifePaul Stoffels isn’t giving up on the cell therapy plans he had at Galapagos, the Belgian drug developer that he tried turning around as CEO before abruptly departing last year. Stoffels is behind a new ...STAT+: On Wall Street, there’s trouble stirring for biotechOn Wall Street, the real trouble for biotech, and the reason for investor angst, lies below the surface.Who is getting weight loss jags on the NHS in Scotland?Fewer than 800 Scots have received jabs for weight loss on the NHS despite them being approved for use three years ago, BBC News has found.No money for new emergency department, says ministerRobbie Butler says a new ED at Altnagelvin hospital in Derry is a priority but he does not have the money to pay for it.Forty percent of high school students report binge eating in new CDC surveyAbout 40% of high school students reported binge-eating in the past month in a new CDC survey, highlighting how widespread this form of disordered eating is among young people.Opinion: My daughter’s death changed how I understood the nursing shortageHealth systems invest in training, but lose early-career nurses within a few years.Opinion: MyChart said I could opt out of sharing my health data. Figuring out how was maddeningWant to opt out of sharing your personal health data? You may need a notary, writes Alex Rosenblat.Iambic snags $150M IPO for AI-driven cancer pipelineNvidia-backed Iambic Therapeutics will begin trading Thursday after pricing its $150 million initial public offering Wednesday night. The cancer-focused biotech sold 9.38 million shares {$IAM} at $16 apiece. The float adds ...OMass Therapeutics collects $310M to chase Neurocrine, Vertex in genetic adrenal disorderAn Oxford-based drug developer has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in the footsteps of Neurocrine and Vertex-acquired Crinetics in an endocrinology ...Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared to “go slow before we go fast.”I'm 12 and I want to try protein powder - should I?We asked experts how safe it is for children and teenagers to take protein supplements.Former FDA officials blast DOGE as ‘one of the biggest disasters in American history’Three former FDA chiefs criticized the DOGE cuts to the agency, saying they robbed the FDA of institutional knowledge that will take years to restore.Warning to women amid shortages of some HRT productsTwo brands of HRT patches, including Estradot transdermal and FemSeven Conti patches, have been affected, the Department of Health has said.As White House shifts focus toward AI and tech, U.S. science leaders defend role of the American universityWhite House planned shift of research funding from universities to industry risks creating a drought in basic research, science leaders sayFewer than 800 Scots have received weight loss jabs on NHS, BBC findsOnly five of Scotland's 14 health boards currently offer the treatment specifically for weight loss, it has emerged.My contraceptive coil saved my life after it revealed I had cancerCaroline Bailey was diagnosed after suffering with "a stabbing pain in the middle of my abdomen".STAT+: Trump administration delays new rule that could restrict imported medicines from Canada and overseasThe Trump administration is delaying by 90 days a federal rule that could prevent Americans from obtaining prescription drugs from licensed international pharmacies.Sanofi's new R&D chief: Western pharma should rethink China's drug pipeline roleSanofi's new R&;D chief said on Wednesday that Western drugmakers cannot ignore China's accelerating innovation and need to consider how the country’s emergence as a global biopharma powerhouse should change their approach to…New FDA framework tilts toward consistency over flexibilityThen-acting FDA leaders said over the summer that regulatory flexibility wasn't the standard they were striving for when the agency gauges rare disease drugs. Now, a more consistent system for assessingHow consumer tech company Whoop is building for Medicare patientsWhoop's chief medical officer, said the company's work with Medicare is an opportunity to prove its ability to improve health at the population level.What Could Medicaid Work Requirements Mean for SSI Applicants?Medicaid work requirements may make it more difficult for some SSI applicants to maintain coverage due to the added complexity of navigating the verification process for the medical frailty exclusion. KFF's policy analysis…What Could Medicaid Work Requirements Mean for People with Disabilities Waiting for Medicare Coverage?This analysis finds that Medicaid covered over 1 in 4 SSDI applicants and beneficiaries waiting to become eligible for Medicare (120,300 people out of a total 415,300 in 2023). In future years, people applying for and new to SSDI…Man, 70, died of eye cancer after scan concerns weren't followed upA coroner warns there's a risk of future deaths due to "substantial delays" in ophthalmology follow-ups.Verastem makes its stand as a RevMed competitor in pancreatic cancerVerastem Oncology had a big Wednesday morning: It announced new data amid a tense competition for the next-wave KRAS agents, as well as a $250 million raise and the departure of its CEO. The Massachusetts ...Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slumpPlus news about Sanofi, Pharming, Skyhook Bio and Altay Therapeutics. Ultragenyx Pharmaceutical sells second PRV this month: The commercial-stage rare disease drugmaker sold its second priority review voucher for $203 million ...STAT+: FDA adcomm members’ ties to industry under scrutinyNew research found that nearly 40% of FDA advisory meetings held over a recent 20-year period included either a patient or consumer rep with active ties to an advocacy group…STAT+: Pharmalittle: We’re reading about Sanofi settling an EU antitrust probe, ‘pharma bro’ Shkreli, and moreThe FTC asked a U.S. court to hold Martin Shkreli in contempt for “flagrantly” violating a court order banning him from working in the pharma industrySTAT+: The startup chasing ‘general biological intelligence’In this edition of AI Prognosis, Brittany Trang talks to Eric Nguyen, the CEO of Radical Numerics, a startup pursuing "general biological intelligence.'Vir makes solid tumor T cell engager deal with GileadVir Biotechnology and its CEO Marianne De Backer have notched yet another deal, this time with Gilead. Gilead will pay Vir $65 million upfront, with another $45 million in near-term milestones. Gilead's also paying a ...Individual Market Enrollment Continues to Fall Through Mid-2026Enrollment in the individual health insurance market fell by 18%—over 4.6 million people—from 25.2 million in June 2025 to 20.5 million in June 2026. This represents an even steeper drop in enrollment than had previously been…STAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccineE.U. antitrust regulators accepted concessions from Sanofi to settle a probe into an allegedly “misleading” campaign that disparaged a rival flu vaccine.New study examines GLP-1 impact on interactions with criminal justice system, employment, housing stabilityA wave of clinical trials have begun to test the ability of GLP-1 weight loss drugs to quell various substance use disorders, with some promising results. A new trial announced…Arrowhead’s brain-targeting RNA drug lowers Alzheimer’s protein in early studyArrowhead Pharmaceuticals has shown that a genetic medicine administered as a subcutaneous injection can seemingly travel into the brain and lower levels of tau, a protein implicated in Alzheimer’s disease. The company found that…Zealand inks up to $1.3B deal for AI-designed obesity treatmentsZealand Pharma said Tuesday it will develop new protein-based treatments for obesity and other metabolic diseases with the help of Generate Biomedicines’ AI technology. The Danish drugmaker is spending $30 million upfront for two…GSK could cut more than 1,200 jobs in BelgiumGSK will make up to 1,217 workers redundant from its sites in Belgium as part of the cost-cutting initiative CEO Luke Miels announced in July. “The proposed changes announced in Belgium today ...Bryant attacks 'irresponsible' Stormont ministers over budgetThe Secretary of State says there is little 'financial accountability or responsibility' across Northern Ireland's executive.Opinion: How states can resist the potential Trump vaccine shortages“States can serve as a last line of defense against the Trump administration’s anti-vaccine policy,” writes Joel Dodge.Opinion: We think a baby’s gut microbiome could be key to lifelong brain health“We need more rigorous, large-scale research into the gut-brain axis across the life course,” write Holly Baines and George Vradenburg.STAT+: Lobbyists and trade groups fight to shape how states regulate medical AILobbying groups for doctors and hospitals and trade groups are working behind the scenes on how to regulate AI in medicine.Swimmer Archie Goodburn to meet prime minister over cancer fundingThe Scottish athlete, who has inoperable brain tumours, previously made a tearful plea for more investment in brain cancer research on BBC Breakfast.'I could never hear on my left side - until I got a prosthetic ear'Stephen Gilbert, 74, was born with unilateral microtia, a rare condition in which the external ear is underdeveloped or missing on one side.STAT+: BlackRock to buy majority stake in Humana’s CenterWell clinics for $2.8 billionHumana is swapping out private equity sponsors for its CenterWell Senior Primary Care clinics. Good bye, Welsh, Carson, Anderson & Stowe. Hello, BlackRock.FTC accuses Martin Shkreli of violating lifetime pharma banMartin Shkreli is under FTC scrutiny once again. The agency and seven states asked a New York federal court on Tuesday to hold Shkreli in contempt for allegedly violating a court-ordered lifetime ban from the ...HHS Public Health Policy Actions Under the Trump Administration 2025-2026A comprehensive timeline of public health policy actions by the Department of Health and Human Services (HHS) under the Trump administration from 2025-2026, with key dates, descriptions, and impacts.Novartis quietly returns a key antibiotic to US marketThere is some good news in the world of antibiotics. Novartis quietly snagged supplemental FDA approval for its drug Lamprene over the summer, transitioning a decades-old leprosy drug to the commercial market, which may boost ...Helen Branswell, whose reporting on infectious diseases and public health drew acclaim, dies at 69Helen Branswell, STAT's infectious disease reporter who earned the respect of experts and public health officials with her accessible, prescient dispatches, has died at age 69.Nearly Three-Quarters of Medicare Advantage Enrollees Could be Denied a Medigap Policy Due to a Pre-Existing ConditionThis analysis examines the share of Medicare Advantage enrollees who have a pre-existing condition that could result in a Medigap denial if they seek to switch to traditional Medicare outside their one-time 12-month trial period…Medigap Guaranteed Issue Requirements: An Overview of Federal and State RulesThis issue brief analyzes federal and state rules related to guaranteed issue requirements for Medigap policies and how they impact beneficiaries’ access to Medigap, including the implications for Medicare beneficiaries with…Key Facts About Medigap Enrollment and Premiums for Medicare BeneficiariesThis brief presents facts about Medigap, including the characteristics of Medicare beneficiaries with a Medigap policy, variation in Medigap enrollment by state, and Medigap premiums.STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis findsNearly 40% of FDA advisory committee meetings over a 20-year period included either a patient or consumer rep with active ties to an advocacy group funded by pharma companies.Verdiva cans mid-stage obesity trial of GLP-1 pill, citing 'market evolution'Verdiva Bio, one of the best-funded private biotechs seeking to get into the lucrative obesity drug market, has terminated one of the Phase 2 trials of its lead asset, a spokesperson ...Soufflé gets $135M for three RNA medicinesA Bob Langer-affiliated startup has collected a megaround financing to advance at least three experimental oligonucleotide medicines. The Massachusetts and Germany biotech, Soufflé Therapeutics, uncorked a fresh $135 million in…Global COVID-19 TrackerThis tracker provides data on global COVID-19 cases and deaths by country, region, and income-level. Additionally, the tracker reports current closure, economic, and health system policy responses to the COVID-19 pandemic…STAT+: Animosity in North Carolina, and MA shooting starsIn this edition of Health Care Inc., we examine the controversy around the health plan covering North Carolina's public workers and retirees, and more.STAT+: Doctors are giving generously to doctors running for officeDoctors have a lot on the line in the next couple years, and they are donating big to doctors running for political office.Beam suggests it can correct mutation; Pfizer to collaborate with EnodiaBeam's first data on a rare disease gene editing therapy: Beam Therapeutics shared initial data from a Phase 1/2 trial of a base editing therapy for glycogen storage disease type Ia ...Rudy Tanzi has long wanted to prevent Alzheimer's. He may be closeFor decades, Rudolph Tanzi has dreamt of a “little white pill” to prevent Alzheimer’s disease that would be so cheap and so safe, it could practically be added to tap water. Now, Tanzi is finally ...BioNTech’s head and neck cancer vaccine misses first of two goalsAn experimental mRNA cancer vaccine from BioNTech failed to meet one of two primary endpoints in a pivotal trial, adding to the obstacles faced by the company’s pipeline for such treatemts. The therapy, known as ...Why an AI scribe wants to prescribeHealth tech companies have been racing to grow AI scribing tools into software that health systems can use more broadly. Some are leaning into medical billing. Others are serving specific ...STAT+: FTC demands Martin Shkreli divest his pharma stocksThe FTC asked a federal court to hold Martin Shkreli in contempt for violating a court order banning him from working in the pharmaceutical industrySTAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and morePatient advocates and some experts are expressing growing alarm over the perceived risks of a Neurocrine Biosciences rare disease drugSTAT+: Takeaways from an evaluation of Google’s diagnostic chatbot, AMIEIn this edition of STAT Health Tech: A look at a study recently published in The Lancet about Google's diagnostic chatbot, AMIE.Readily raises $11M to help insurers stay compliantA startup that uses AI to help insurers keep track of changing rules and stay compliant just raised $11 million, Endpoints News learned exclusively. San Francisco-based Readily tracks and flags changes in government regulations…Mum told to prepare for 'worst' urges others to get respiratory illness vaccineJo Goldsmith said the RSV vaccine was not available when she was pregnant, but that she would have had it.How many ways can the Trump administration clamp down on international researchers?In the span of two days last week, the Trump administration issued two sweeping announcements meant to crack down on international students and scholars, who make up a sizable portion…Paragon spins out ninth biotech, sending cardiopulmonary drugs to AlaunosParagon Labs has created a ninth company, using a reverse merger model that it’s honed over the past four years to send Velaris Therapeutics straight onto the public markets. Velaris completed a transaction on Tuesday ...Apogee execs join Paragon to scale its R&D, company creation engineSome people would think about taking a break for several quarters after selling a biotech for $10.9 billion. Michael Henderson and five of his fellow executives from Apogee Therapeutics are not fading ...'I woke from surgery to find it hadn't been done'Kelly O'Shea says she's "lost faith" in women's health after paying £20k for treatment she needed.Syndax's lung disease ambitions for Niktimvo end with a Phase 2 failureSyndax is ending development of Niktimvo in a rare lung disease called idiopathic pulmonary fibrosis (IPF) after the treatment flunked a mid-stage trial. The company was evaluating Niktimvo in a placebo-controlled Phase 2 study…Roche's seventh China deal this year is a $1.2B obesity pact with Rona TherapeuticsRoche is set to fork over up to $100 million in upfront and near-term milestone payments to license an asset in a red-hot field for obesity: ALK7 inhibition. The deal, with the RNA interference specialist ...AI in Health Care: Who Gets Left Behind?Health care's AI future is being built right now. The open question is “for whom?” Dr. Uché Blackstock — emergency physician, former associate professor at NYU School of Medicine, founder and CEO of Advancing Health Equity, and…Opinion: Lethal injection will never be the same after Christa Pike’s botched execution“The legal and medical issues in the Christa Pike case are on a collision course,” writes bioethicist M. Sara Rosenthal.Opinion: STAT+: The epidemic of learned helplessness in physicians“Hordes of brilliant, graduate-degree-holding professionals in their 40s, 50s, and beyond act helpless at work,” writes STAT columnist Frances Mei Hardin.STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drugPatient advocates and some experts are expressing growing alarm over the perceived risks of a rare disease drug sold by Neurocrine Biosciences.Cut screen time in classrooms to avoid long-term health issues, government urgedA group of clinicians warns technology use in English schools is driving a rise in health problems like short-sightedness.'I was dead for 10 minutes, but lived to tell the tale'Medics in Spain raced against time to save Sandra McCartney's life after her heart stopped beating.I lost my hair to chemo - now my wigs are worn by A-list starsAntonia Okonma Shittu's wig business was launched after a shock diagnosis, and she now wants to help other women feel their best.I've woken from operations to find the surgery hasn't been done - women's health is brokenKelly O'Shea felt there was no alternative but to pay £20,000 for the treatment she needed out of desperation.Merck reports mixed data for Lucentis competitor in diabetic macular edemaMerck’s ophthalmology candidate, remigromig, met the primary endpoint in a pivotal study, but the full results raise questions about the drug’s commercial prospects. Merck said last month that remigromig was non-inferior to ...Asahi Kasei lands approval for new HSV treatmentJapanese pharma Asahi Kasei Therapeutics has snagged FDA approval for a herpes treatment that it acquired early this year in an almost $1 billion deal. The late Friday approval of Hovilpri ...Mirum succeeds in rare liver disease trial; First Tracks delivers in celiacMirum Pharmaceuticals’ late-stage win in ultra-rare liver diseases: The company’s ileal bile acid transporter inhibitor Livmarli significantly reduced cholestatic pruritus versus placebo in patients with cholestatic liver…Bristol Myers reveals a pair of Phase 3 wins for fibrosis, RayzeBio drugsBristol Myers Squibb reported two Phase 3 successes on Monday morning, including for an experimental drug that recently ran into safety issues. A trial testing the lung disease program admilparant succeeded ...Brent Saunders out as Bausch + Lomb CEO, abrupt end to three-year runBrent Saunders, one of biopharma’s most prominent dealmakers and highest-paid leaders, is out as CEO of Bausch + Lomb, failing to add another multibillion-dollar company sale to his resume. In aGSK to invest $800M for new R&D, manufacturing hub in PennsylvaniaGSK has budgeted more than $800 million to grow its Pennsylvania footprint, its second expansion in the state in two years. The company will begin construction in 2027 at its current site ...Undecimal Bio launches with $18M to take siRNA beyond liver diseaseAfter spinning out one half of its business this summer, Eleven Therapeutics is carving out the other half with $18 million to join companies like Arrowhead and Alnylam that ...Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?In the latest news, Novo Nordisk has entered a collaboration with Anthropic aimed at speeding the discovery and development of new medicines. An initial project will test Anthropic's Claude Science on specific R&;D workflows…Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in LineRecently, Iambic Therapeutics has filed to go public on Nasdaq under the ticker IAM, adding another closely watched name to a biotech IPO market that has begun to reopen after one of its weakest years in recent memory.Into the Dark: Finding Novel Drug Targets Within the Depths of Our ProteomeDrug discovery has never had a richer therapeutic toolbox. Antibody-drug conjugates, antisense oligonucleotides, CRISPR therapeutics, RNA medicines, CAR-T cells, PROTACs, and molecular glues have transformed how medicine can…The $2.7B Question: How Do We Know If Isomorphic's AI Works?Isomorphic Labs has raised about $2.7 billion from outside investors since 2025. Its president, Max Jaderberg, says its drug design engine works, but the company has not publicly named a drug candidate.The Bigger Point Beyond Insilico's Aging Research MilestoneThis week Insilico Medicine , an AI-driven drug discovery company, reported an unusual experiment. Arguably for the first time, aging biomarkers were written prospectively into a controlled trial run for a conventional disease…The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?An article published in Nature Biotechnology on 7 September 2026 by Alex Zhavoronkov’s team at Insilico Medicine and collaborators marks an important step forward for the field of drugs targeting aging. Using proteomics-based…Three AI Drug Discovery Startups Raise $526 Million in Two DaysThree AI drug discovery companies raised a combined $526 million on September 23 and 24. One mines plants and microbes for new medicines. One trains its models on what it calls the world's largest proprietary genomic dataset. The…What Do the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences?Last week, Anthropic and OpenAI released new frontier models, specifically, Anthropic shipped Claude Fable 5.1 and a restricted variant called Mythos 5.1, while OpenAI shipped GPT-6 Astra . OpenAI president, Greg Brockman went as…When Agents Run Computations: Schrödinger’s Robert Abel On Where The Human Still DecidesGenerating drug candidate ideas has become inexpensive, and the supply of hypotheses now exceeds any organization’s capacity to evaluate them. Schrödinger’s answer, launched at the end of July , is Bunsen: an agentic AI…WhiteLab Genomics Raises $26M to Scale AI-designed Delivery Systems for Cell and Gene TherapiesTechbio company WhiteLab Genomics has raised a $26 million Series B to develop and license its own AI-designed gene delivery technologies, moving beyond the computational services business it started with. Founded in 2019 by…Stormont 'failing to plan' for ageing populationPoliticians are urged to prepare as over-65s are projected to outnumber children in NI by next year.Teen 'detached from reality' to cope with return of aggressive cancerEthan found out his cancer had returned two weeks after successful treatment.Childhood cancer symptoms can be easily missed - here's what to look out forAlthough rare, cancer is the leading cause of death from disease among children under 15 in the UK.AstraZeneca blames trial design for Phase 3 failure of bone disease drugNew details from AstraZeneca's failed Phase 3 trial of its enzyme replacement therapy for a genetic bone disease suggest the test missed its goals because of how the trial was composed, as the drugmaker seeks ...'It shows you there is hope': Football coach on anorexia recovery journeyJordan Caldwell, who once struggled to see a future beyond anorexia, says bodybuilding gave him a new purpose in life.Americans trust science more than peers around the world, survey showsJust 40 percent of Americans reported a lot of confidence in U.S. hospitals and health clinics, the same proportion as in Portugal and Uruguay.Women in Biopharma 2026; A secretive new thorn in pharma’s side; and moreWelcome back to Endpoints Weekly! We unveiled our 2026 Women in Biopharma special project on Monday. Our team pored through nearly 200 nominations to reach this year’s list of 20 honorees. You can check out ...
New WHO technical package to help countries improve health data for COVID-19 response and beyondToday, as part of its commitment to strengthening health information systems and improving health[1], especially in the context of the COVID-19 pandemic, WHO announced a new approach to improving access to life-saving data: the…Parkinson's cell therapy biotech Aspen and I&I startup Bambusa file for IPOsA Gilead-backed cell therapy maker and an I&;I biotech from BioNTech vets are looking to ride the biotech industry's IPO momentum. Aspen Neuroscience and Bambusa Therapeutics are the latest drug developers to ...STAT+: Biotech leader, leading lab leak theorist no longer in consideration for top infectious disease roleSteven Quay, a biopharmaceutical executive with no background in infectious diseases, is no longer being considered for director of the National Institute for Allergy and Infectious Diseases.STAT+: Hospitals sue – again – to halt Trump administration’s 340B rebate pilotThe AHA is once again suing the Trump administration over its plan to revamp a federal drug discount program into one that provides after-the-fact rebates instead of upfront discounts.Curium prices generic radioligand at 5% discount to Novartis' LutatheraCurium has set the list price for Bexlutry, its radiosimilar to Novartis’ Lutathera, at $63,524 per infusion — about a 5% discount to the cost of the pharma giant’s drug. Challenging Novartis in the tricky field ...STAT+: Pharma’s free lunches for doctors boost inappropriate prescribing, analysis findsThe gifts and payments that doctors receive from drugmakers increased inappropriate prescribing, likely leading to rising health care costs, according to a new review.STAT+: Medicare Advantage star ratings trigger new bonuses, and uncertaintyThe federal government has released new quality ratings for Medicare Advantage insurers for 2027, with Humana emerging as the biggest winner.STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drugLife Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.New data on RevMed’s Rasonque leave potential opening for other treatmentsPatients with the most common KRAS mutation in pancreatic cancer appeared to have a lower response rate than the overall patient population with Revolution Medicines’ Rasonque, sending the company’s shares {$RVMD} down more than…Acting general counsel at HHS has left the departmentThe acting general counsel at HHS, Bob Foster, is no longer at the agency. When Endpoints News contacted Foster through his government email, it received the following automated message: “I am no longer with the ...HHS’s Elimination of Disparate Impact to Determine Discrimination: Potential Implications for Health and Health CareThis brief provides background on Title VI, summarizes the key changes in the 2026 final rule, and discusses the potential implications for racial and ethnic health disparities.City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debutPlus news about Alchemist Capital, Newron Pharmaceuticals, Life Biosciences, Onyx Bio and Tecentriq. City Therapeutics charts $158M IPO: The RNAi startup from former Alnylam executives is looking to sell 9.72 million shares at…STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.How these census changes could threaten public healthThe Trump administration wants to make three big changes to the U.S. Census, including eliminating questions about race, ethnicity, and sexual orientation and excluding anyone who is not a citizen…STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and moreThe FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma news.How Much Do People with Medicare Pay for Coverage?While Medicare covers a wide range of health care services, Medicare beneficiaries generally pay out-of-pocket for their monthly premiums, deductibles, and cost sharing for Medicare covered services. This brief provides an…Medicare Advantage Plan Availability Varies Widely by County for 2027The analysis shows that plan level Medicare Advantage prescription drug availability varies widely across the country in 2027, with a modest reduction in the share of enrollees having more than 40 MA-PDs to choose from compared…Medicare Open Enrollment and Coverage Options: Key Questions and AnswersEach year, Medicare beneficiaries have an opportunity to make changes to how they receive their Medicare coverage during the nearly 8-week annual open enrollment period. This brief answers key questions about the Medicare open…Autism, ADHD and mental health review: What you need to knowIt contains big lessons for the NHS, welfare, education and employment policies. What are the key takeaways?From the workplace to pop culture - why how we view women's anger is changingStudies suggest women are getting angrier, but are they just more open about it?Chai Discovery signs GSK deal to make biologics with AIAt the start of 2026, Joshua Meier pitched his startup's collaboration with Eli Lilly as just the beginning. Meier's vision of a "year of deployment" has been more than an aspiration, as ...Viking commercial chief is out in a hurry; Gilead looks to BeOne exec for China expansion→ Neil Aubuchon only lasted nine months as chief commercial officer of Viking Therapeutics, leaving Peer Review to wonder what’s going on with the strategy for its obesity drug. Is it really justOpinion: 50 years ago, my colleagues and I pursued basic research science that became revolutionary“Basic studies led to clinical and translational advances that no one could have predicted,” Robert Gallo writes of his work with interleukin-2.Opinion: Proposed U.S. census changes could be catastrophic for public health“Erasing data does not erase need or harm,” writes social epidemiologist Nancy Krieger.STAT+: Will MAHA survive the midterms?As the midterm elections draw near, the MAHA movement is nearly invisible on the campaign trail and struggling to find a financial or messaging foothold in key races.The fall of Roe dramatically changed abortion access. This researcher used Reddit to capture howWith research on abortion access barriers, STAT Wunderkind Betsy Pleasants is defining a framework for using AI tools without losing sight of the people behind the data.TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertensionThe appetite for biotech IPOs remains strong, especially when Eli Lilly and Nobel Prize-winning science are involved. TRexBio priced its initial stock sale Thursday, raising $116.7 million in ...Trump administration investigates 9 universities for alleged visa fraudThis story has been updated. The Trump administration announced Thursday that it is investigating nine universities for alleged fraud related to visas commonly used by postdoctoral researchers, a core part…ADHD and autism at risk of over-diagnosis, says government reviewThe review, which focuses on younger people, warned there was a risk society was moving from an era of under-diagnosis to over-diagnosis.STAT+: House Democrat seeks to scrap No Surprises Act’s costly arbitration processA new proposal in Congress to scrap a surprise billing ban’s controversial arbitration system will need to to survive an onslaught of attacks from provider groups.Harry says he 'slipped into depression' after leaving UKThe Duke of Sussex says he had an "adrenaline crash" while visiting Vancouver Island to "get some space".New PDUFA deal sets aside FDA money to rehire reviewersTop pharmaceutical trade groups say the FDA will have a dedicated pool of money to replenish its stable of reviewers as part of the new Prescription Drug User Fee Act (PDUFA) agreement, after HHS layoffs ...KFF Tracker: America First MOU Bilateral Global Health AgreementsThis tracker provides up-to-date information on countries with signed bilateral MOU global health agreements with the U.S.Viatris to make $1.65B Pacira acquisition, adding to momentum in painViatris, a generics and branded medicines maker, is buying into non-opioid pain drugs with a cash acquisition of commercial-stage Pacira BioSciences. The Thursday morning deal, valued at $1.65 billion, follows a ...Robotics company Multiply Labs nets $75M; Isotope maker NorthStar gets up to $185MPlus, news about Roche’s Genentech and Fresenius Kabi. Multiply Labs collects $75M: The robotics biomanufacturing company’s Series B raise will be used to increase its capacity and headcount as it moves ...Ono pays Biohaven $80M for protein degrader; UK pulls Valneva's chikungunya shotPlus news about ADC Therapeutics, Atrium Therapeutics, Bristol Myers, Novartis and Pfizer. Biohaven partners with Ono: Tokyo-based Ono Pharmaceutical has agreed to pay Biohaven $80 million upfront to license its pan-IgG ...Endeavor notches major mid-stage trial win, says IPF drug can reverse diseaseEndeavor BioMedicines said its treatment for a chronic lung disease succeeded in a mid-stage test, claiming the drug had the potential to reverse the course of idiopathic pulmonary fibrosis in a ...Congressional District Interactive Map: Medicaid Enrollment by Eligibility GroupKFF’s new interactive maps illustrate Medicaid enrollment by congressional district and eligibility group. In half of Republican congressional districts, at least 20% of residents are enrolled in Medicaid, and in half of…'Ominous signs' of winter pressures as NHS waiting list growsNHS winter pressures appear to be building already, with rises in waiting times for planned surgery.How Does ACA Marketplace Enrollment in 2026 Vary Across Congressional Districts?KFF’s new interactive maps illustrate ACA Marketplace enrollment and changes in enrollment by congressional district and state. Marketplace enrollment declined in most congressional districts between 2025 and 2026, with…AI in Health Care Moves Toward More Autonomous Roles — The MonitorFederal health agencies are testing AI applications that move into patient care typically handled by physicians. And recent research suggests people may place more trust in conversational AI, while false claims attributed to…Women’s Access to Fertility CareThis analysis presents findings from the 2026 KFF Women’s Health Survey on women's reported need for and use of fertility services.Women’s Experiences with and Attitudes Towards Family Support PoliciesThis analysis highlights women’s opinions regarding the possible impact of potential federal actions on their decision to have children in the future as well their experiences with paid parental leave and sick leave in the…'I was blamed for my baby's death, now NHS needs to change'Neil and Katie Russell are working with the hospital where their daughter died on the scheme.U.S. Foreign Aid Freeze & Dissolution of USAID: Timeline of EventsThis timeline provides a detailed overview of actions, including counter-actions, related to the administration’s efforts to freeze all U.S. foreign aid and dissolve the U.S. Agency for International Development (USAID).Overview of President Trump’s Executive Actions on Global HealthThis guide provides an overview of executive orders and other executive actions made by the Trump Administration since January 21, 2025 that directly address or affect U.S. global health efforts. This resource identifies each…Litigation Involving Reproductive Health and Rights in the Federal CourtsThis State and Federal Reproductive Rights Litigation tracker aggregates information about ongoing litigation regarding abortion bans and restrictions, FDA approval of Mifepristone (an abortion pill) and other federal regulations.First Look at New Hospital Price Transparency Provisions: Some Factors Complicate Price ComparisonsThis analysis takes a first look at how hospitals are reporting prices under updated federal hospital price transparency requirements that took effect in January 2026.Tracking Insurer Participation Changes in the ACA Marketplaces in 2027This interactive tracks announced insurer exits from and entries into the ACA Marketplaces for 2027.New global guidelines warn against obesity drugs for children under 10Care should focus on healthy eating and exercise, not medicines such as weight-loss injections, says the World Health Organization'That nagging feeling of dread': Is 'hang-xiety' a real thing?For some, a hangover can start an anxious spiral. We spoke to experts about the reasons why.One million UK people who have never smoked are now vapingLatest statistics also show, for the second year in a row, more over-16s vape than smoke.